Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calypso Medical, a privately held medical device company, has launched the Aim clinical study using the company's GPS for the Body technology for patients receiving radiation therapy for prostate cancer.
Subscribe to our email newsletter
The primary objectives of the study are to evaluate acute and chronic quality-of-life assessments and complications related to external beam radiation therapy in prostate cancer patients when the Calypso 4D localization system is used for managing motion.
The study protocol recommends the delivery of high doses of radiation (81Gy) to the prostate during 45 treatment sessions with tighter treatment margins while using the Calypso system to manage prostate motion. Patient enrollment is already underway in the 300-patient study.
Eric Meier, CEO and president of Calypso Medical, said: “Calypso Medical’s technology allows clinicians to manage motion as it occurs and adapt treatment, ensuring that the tumor target is always aligned with the radiation beam. With the higher doses and tighter treatment margins used in the Aim study, motion management becomes even more essential.”
Constantine Mantz, principal investigator, said: “The data from this study will reinforce the importance of the management of prostate motion during daily treatment with tight treatment margins.
“Calypso’s technology enables radiation oncologists to treat patients with confidence that the tumor target is continuously aligned with the radiation beam throughout each treatment session. Since we treat patients with tight margins daily for 40 to 45 days, it is critical we know where the prostate is at all times. The clinical goal is to achieve the best control of the cancer while minimizing side effects.”